Regulatory Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe Pharmaceutical TechnologyLilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults.OncologyRead full story pharminent June 29, 2026 (Last updated: June 29, 2026) Pharmaceutical Technology Lilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and ZepboundNext: Ipsen charts $1.75bn course for Kartos acquisition Related Stories Regulatory Celcuity gains FDA approval for closely watched breast cancer drug pharminent July 15, 2026 Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug pharminent July 15, 2026 Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi pharminent July 14, 2026
